^
    Back
    Association details:
    Biomarker:PTEN N323fs*21
    Cancer:Prostate Cancer
    Drug:everolimus (mTOR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    S. Karger AG
    Title:

    Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation

    Published date:
    04/27/2020
    Excerpt:
    A 67-year-old male was noted to have an elevated prostate-specific antigen (PSA)...Further testing included a prostate biopsy that demonstrated Gleason grade 5 + 4 = 9 prostate adenocarcinoma in both lobes of the prostate…After being heavily pretreated, the patient showed stable disease on everolimus...
    DOI:
    10.1159/000506625